An observational study in COVID-19, sponsored by Wissenschaftliches Institut Bethanien e.V. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by Wissenschaftliches Institut Bethanien e.V · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.
Among the 226 studies in COVID-19 with a site in Germany, this one is the 88th largest by enrollment of the 94 observational ones that give a count, is one of 109 that started in 2020, is one of 94 observational ones, and was the 70th registered.
7,994 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in Germany, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
226 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 48 · Phase 3 46 · Phase 4 5
First in 2016; this study’s year is marked. 109 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 135 across the 130 interventional studies, 410 across the 94 observational. Of the 153 that completed or were terminated, 48 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 226 have an industry lead sponsor. The 10 most frequent:
Wissenschaftliches Institut Bethanien e.V is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
Wissenschaftliches Institut Bethanien e.V has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
9 of the studies in COVID-19 with a site in Germany that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05389319University Hospital TuebingenA Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 226 studies in COVID-19 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is an epidemiological observational study. It serves to collect data from patients with positive COVID-19 test results who are hospitalized. All data describing the course of the inpatient stay are recorded (Length of stay, course of therapy, medication, X-ray and CT results,ventilation mode and duration, laboratory). Furthermore, anthropometric data and information on COVID-19 symptoms is recorded.
The aim of this study is to describe the course of disease and the treatment of patients suffering from COVID-19 who are hospitalized and treated as inpatients:
All patients who are inpatients at Bethanien Hospital and have a proven COVID-19 infection and who agree to participate in the study during the period from 01.08.2020 - 30.05.2021.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
convalescence/death
has patient died or has patient recovered
Time frame: through study completion, an average of 2 months
length of stay in the intensive care unit
length of stay in the intensive care unit
Time frame: through study completion, an average of 2 months
length of stay in hospital
length of stay in hospital
Time frame: through study completion, an average of 2 months
Ran from Aug 2020 to primary completion in May 2021, 9 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 9 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wissenschaftliches Institut Bethanien e.V